The largest systematic review of medicinal cannabis ever conducted, published in The Lancet, has found no evidence that it effectively treats anxiety, depression or PTSD. The meta-analysis covered 54 randomized controlled trials spanning 45 years and nearly 2,500 patients. Lead author Dr. Jack Wilson from the University of Sydney's Matilda Centre warned that routine use "could be doing more harm than good" by increasing risks of psychotic symptoms and cannabis use disorder while delaying proven treatments.
The findings are significant given that roughly 27% of people aged 16-65 in the U.S. and Canada report using cannabis medically, with about half citing mental health as their reason. The study did find limited evidence that cannabis may help with insomnia, autism and tics or Tourette's syndrome, though the data remains weak.
Researchers urged regulators to reconsider approving medicinal cannabis for psychiatric conditions without stronger clinical evidence, noting the gap between public perception and scientific data continues to widen.
